U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06963502) titled 'A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors' on April 16.
Brief Summary: This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in and Colorectal cancer(CRC) and non-Small cell lung cancer (NSCLC).
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Colorectal Cancer
Non-Small Cell Lung Cancer
Intervention:
DRUG: HS-103...